Compare FIP & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIP | KMDA |
|---|---|---|
| Founded | 2021 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.1M | 460.3M |
| IPO Year | 2021 | 2013 |
| Metric | FIP | KMDA |
|---|---|---|
| Price | $4.93 | $7.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 831.7K | 43.6K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | 2.12% | ★ 3.08% |
| EPS Growth | ★ 16.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $502,520,000.00 | N/A |
| Revenue This Year | $58.19 | $13.94 |
| Revenue Next Year | $30.58 | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | ★ 51.59 | N/A |
| 52 Week Low | $3.90 | $6.50 |
| 52 Week High | $7.93 | $9.35 |
| Indicator | FIP | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 39.79 |
| Support Level | $4.56 | $7.35 |
| Resistance Level | $6.23 | $7.45 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 82.67 | 36.69 |
FTAI Infrastructure Inc is engaged in five segments; Railroad segment, which includes eight freight railroads and one switching company that provide rail service to certain manufacturing and production facilities; the Jefferson Terminal segment, which consists of a multi-modal crude oil and refined products terminal and other related assets; The Repauno segment, which consists of a deep-water port located along the Delaware River with an underground storage cavern, a multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities; Power and Gas segment, which comprised Long Ridge, a multi-modal terminal located along the Ohio River; and Sustainability and Energy Transition segment, which comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.